Table 2. Serum 25(OH)D concentrations (ng/mL) by early virologic response (≥ 2-log10 decline in HCV RNA level from baseline to week 12).
Study | Race | Early virologic response | P* | |||
---|---|---|---|---|---|---|
Yes | No | |||||
n | Median (IQR) | n | Median (IQR) | |||
HALT-C † | European Americans | 373 | 21.9 (16.7–27.4) | 341 | 23.0 (16.2–30.0) | 0.261 |
African Americans | 48 | 12.5 (8.9–17.1) | 111 | 11.5 (8.4–16.4) | 0.456 | |
VIRAHEP-C ‡ | European Americans | 126 | 27.0 (21.1–34.4) | 71 | 25.9 (18.8–36.2) | 0.696 |
African Americans | 76 | 13.7 (11.0–21.1) | 108 | 15.1 (10.7–20.1) | 0.370 |
* P-value for Brown-Mood test, two-sided normal approximation
† n = 38 HALT-C participants did not have HCV RNA levels measured at a week 12 and were thus excluded from the EVR analysis
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; HCV, hepatitis C virus; IQR, interquartile range